Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Ranging Study of Novartis Meningococcal B Recombinant Vaccine in Infants
NCT00937521Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2009
- Primary completion
- Nov 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, single-blind trial of recombinant neisseria meningitidis group B nhba fusion protein in meningococcal meningitis and meningococcal disease (8 arms), sponsored by Novartis. Primary endpoints: Percentages of Subjects With Serum Bactericidal Activity (hSBA) >= 1:5 and Number of Subjects With Fever >= 38.5 C. Started Jul 2009; status: completed.
02
Drugs
recombinant neisseria meningitidis group B nhba fusion protein
03
Conditions
meningococcal meningitismeningococcal disease
Beyond the preview
Go deeper on NCT00937521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00937521.